Impact of anti-HDV reflex testing at HBs antigen positive discovery in a single center France : Support for primary HDV screening in France
Copyright © 2024. Published by Elsevier B.V..
BACKGROUND: Hepatitis Delta virus (HDV) infection is a major cause of liver-related morbidity and mortality in patients infected with HBV, with a global HDV prevalence uncertain. In France, 2 to 5 % of HBs antigen (HBsAg) carriers present anti-HDV antibodies (anti-HDV). The EASL recommends testing for anti-HDV in all HBsAg-positive patients. Since January 2022, we have systematically carried out anti-HDV serology when a positive HBsAg is discovered (new HBsAg carriers).
OBJECTIVES: We evaluated the benefit of anti-HDV reflex testing after one year of practice by comparing anti-HDV and HBsAg serology data over the last six years, among the new HBsAg carriers and all the HBsAg carriers.
STUDY DESIGN: HBsAg and anti-HDV were screened using the Abbott Architect HBsAg quanti kit and the DIA.PRO HDVAb kit. Serological, demographic, virological, and clinical data were analyzed.
RESULTS: Implementing anti-HDV reflex testing leads to more than a 2-fold increase in diagnoses of HDV infection among all HBsAg carriers. If the anti-HDV positive rate remains stable among the new HBsAg carriers, a significant increase in the anti-HDV positive rate from 6.8 % to 10.3 % was observed considering all HBsAg carriers. Interestingly, the discovery of anti-HDV carriage increased from 3.9 % to 6.5 % in 2022, allowing earlier identification of HBV-HDV-infected patients and a fast referral to hepatologists for adequate clinical management and, in some cases, the introduction of bulevirtide-based therapy.
CONCLUSIONS: Our preliminary results at one year seem promising and evaluating the cost-effectiveness of reflex tests in real life with feedback would be helpful.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:171 |
|---|---|
| Enthalten in: |
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 171(2024) vom: 02. Apr., Seite 105650 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parfut, Assilina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
HDV prevalence |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 02.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcv.2024.105650 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368402827 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368402827 | ||
| 003 | DE-627 | ||
| 005 | 20240403000229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcv.2024.105650 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1361.xml |
| 035 | |a (DE-627)NLM368402827 | ||
| 035 | |a (NLM)38350177 | ||
| 035 | |a (PII)S1386-6532(24)00012-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Parfut, Assilina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of anti-HDV reflex testing at HBs antigen positive discovery in a single center France |b Support for primary HDV screening in France |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: Hepatitis Delta virus (HDV) infection is a major cause of liver-related morbidity and mortality in patients infected with HBV, with a global HDV prevalence uncertain. In France, 2 to 5 % of HBs antigen (HBsAg) carriers present anti-HDV antibodies (anti-HDV). The EASL recommends testing for anti-HDV in all HBsAg-positive patients. Since January 2022, we have systematically carried out anti-HDV serology when a positive HBsAg is discovered (new HBsAg carriers) | ||
| 520 | |a OBJECTIVES: We evaluated the benefit of anti-HDV reflex testing after one year of practice by comparing anti-HDV and HBsAg serology data over the last six years, among the new HBsAg carriers and all the HBsAg carriers | ||
| 520 | |a STUDY DESIGN: HBsAg and anti-HDV were screened using the Abbott Architect HBsAg quanti kit and the DIA.PRO HDVAb kit. Serological, demographic, virological, and clinical data were analyzed | ||
| 520 | |a RESULTS: Implementing anti-HDV reflex testing leads to more than a 2-fold increase in diagnoses of HDV infection among all HBsAg carriers. If the anti-HDV positive rate remains stable among the new HBsAg carriers, a significant increase in the anti-HDV positive rate from 6.8 % to 10.3 % was observed considering all HBsAg carriers. Interestingly, the discovery of anti-HDV carriage increased from 3.9 % to 6.5 % in 2022, allowing earlier identification of HBV-HDV-infected patients and a fast referral to hepatologists for adequate clinical management and, in some cases, the introduction of bulevirtide-based therapy | ||
| 520 | |a CONCLUSIONS: Our preliminary results at one year seem promising and evaluating the cost-effectiveness of reflex tests in real life with feedback would be helpful | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HDV prevalence | |
| 650 | 4 | |a Hepatitis D virus | |
| 650 | 4 | |a Reflex testing | |
| 650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
| 650 | 7 | |a Hepatitis Antibodies |2 NLM | |
| 700 | 1 | |a Tripon, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Gantner, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Chaffraix, Fréderic |e verfasserin |4 aut | |
| 700 | 1 | |a Laugel, Elodie |e verfasserin |4 aut | |
| 700 | 1 | |a Wendling, Marie-Josée |e verfasserin |4 aut | |
| 700 | 1 | |a Erol, Furkan |e verfasserin |4 aut | |
| 700 | 1 | |a Wiedemer, Carine |e verfasserin |4 aut | |
| 700 | 1 | |a Doffoel, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Saviano, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Royant, Maude |e verfasserin |4 aut | |
| 700 | 1 | |a Habersetzer, François |e verfasserin |4 aut | |
| 700 | 1 | |a Fafi-Kremer, Samira |e verfasserin |4 aut | |
| 700 | 1 | |a Velay, Aurélie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology |d 1997 |g 171(2024) vom: 02. Apr., Seite 105650 |w (DE-627)NLM097223964 |x 1873-5967 |7 nnns |
| 773 | 1 | 8 | |g volume:171 |g year:2024 |g day:02 |g month:04 |g pages:105650 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcv.2024.105650 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 171 |j 2024 |b 02 |c 04 |h 105650 | ||